Annual CAPEX
$4.88 M
-$24.86 M-83.59%
31 December 2023
Summary:
Adaptimmune Therapeutics annual capital expenditures is currently $4.88 million, with the most recent change of -$24.86 million (-83.59%) on 31 December 2023. During the last 3 years, it has risen by +$1.97 million (+67.93%). ADAP annual CAPEX is now -83.59% below its all-time high of $29.74 million, reached on 31 December 2022.ADAP CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CAPEX
$435.00 K
-$319.00 K-42.31%
30 September 2024
Summary:
Adaptimmune Therapeutics quarterly capital expenditures is currently $435.00 thousand, with the most recent change of -$319.00 thousand (-42.31%) on 30 September 2024. Over the past year, it has increased by +$146.00 thousand (+50.52%). ADAP quarterly CAPEX is now -96.52% below its all-time high of $12.49 million, reached on 31 March 2017.ADAP Quarterly CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CAPEX
$2.37 M
+$146.00 K+6.55%
30 September 2024
Summary:
Adaptimmune Therapeutics TTM capital expenditures is currently $2.37 million, with the most recent change of +$146.00 thousand (+6.55%) on 30 September 2024. Over the past year, it has dropped by -$5.11 million (-68.27%). ADAP TTM CAPEX is now -92.21% below its all-time high of $30.47 million, reached on 30 June 2017.ADAP TTM CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ADAP CAPEX Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -83.6% | +50.5% | -68.3% |
| 3 y3 years | +67.9% | -74.0% | -60.3% |
| 5 y5 years | +3.6% | +29.1% | -11.4% |
ADAP CAPEX High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -83.6% | +67.9% | -95.8% | +50.5% | -92.2% | +6.5% |
| 5 y | 5 years | -83.6% | +67.9% | -95.8% | +50.5% | -92.2% | +30.6% |
| alltime | all time | -83.6% | +257.3% | -96.5% | +98.6% | -92.2% | +349.8% |
Adaptimmune Therapeutics CAPEX History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $435.00 K(-42.3%) | $2.37 M(+6.6%) |
| June 2024 | - | $754.00 K(+110.6%) | $2.23 M(-18.0%) |
| Mar 2024 | - | $358.00 K(-56.7%) | $2.72 M(-44.3%) |
| Dec 2023 | $4.88 M(-83.6%) | $827.00 K(+186.2%) | $4.88 M(-34.8%) |
| Sept 2023 | - | $289.00 K(-76.7%) | $7.48 M(-57.1%) |
| June 2023 | - | $1.24 M(-50.8%) | $17.43 M(-30.7%) |
| Mar 2023 | - | $2.52 M(-26.4%) | $25.15 M(-15.4%) |
| Dec 2022 | $29.74 M(+238.7%) | $3.43 M(-66.5%) | $29.74 M(-2.0%) |
| Sept 2022 | - | $10.24 M(+14.3%) | $30.35 M(+39.3%) |
| June 2022 | - | $8.96 M(+25.9%) | $21.79 M(+49.1%) |
| Mar 2022 | - | $7.11 M(+76.0%) | $14.61 M(+66.4%) |
| Dec 2021 | $8.78 M(+202.2%) | $4.04 M(+141.7%) | $8.78 M(+47.0%) |
| Sept 2021 | - | $1.67 M(-6.2%) | $5.97 M(+17.0%) |
| June 2021 | - | $1.78 M(+38.7%) | $5.11 M(+32.7%) |
| Mar 2021 | - | $1.28 M(+4.0%) | $3.85 M(+32.4%) |
| Dec 2020 | $2.91 M(-5.5%) | $1.24 M(+53.9%) | $2.91 M(+27.3%) |
| Sept 2020 | - | $803.00 K(+53.5%) | $2.28 M(+25.6%) |
| June 2020 | - | $523.00 K(+52.0%) | $1.82 M(-21.3%) |
| Mar 2020 | - | $344.00 K(-43.9%) | $2.31 M(-24.9%) |
| Dec 2019 | $3.07 M | $613.00 K(+81.9%) | $3.07 M(+14.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2019 | - | $337.00 K(-66.8%) | $2.68 M(-27.2%) |
| June 2019 | - | $1.01 M(-8.5%) | $3.68 M(-5.6%) |
| Mar 2019 | - | $1.11 M(+406.4%) | $3.90 M(-17.1%) |
| Dec 2018 | $4.71 M(-81.2%) | $219.00 K(-83.7%) | $4.71 M(-26.7%) |
| Sept 2018 | - | $1.34 M(+8.5%) | $6.42 M(-4.2%) |
| June 2018 | - | $1.24 M(-35.5%) | $6.71 M(-53.5%) |
| Mar 2018 | - | $1.91 M(-1.0%) | $14.44 M(-42.3%) |
| Dec 2017 | $25.01 M(+95.6%) | $1.93 M(+19.0%) | $25.01 M(-16.6%) |
| Sept 2017 | - | $1.63 M(-81.9%) | $30.00 M(-1.5%) |
| June 2017 | - | $8.96 M(-28.2%) | $30.47 M(+34.2%) |
| Mar 2017 | - | $12.49 M(+80.5%) | $22.71 M(+77.6%) |
| Dec 2016 | $12.79 M(+30.0%) | $6.92 M(+230.7%) | $12.79 M(+118.0%) |
| Sept 2016 | - | $2.09 M(+74.1%) | $5.86 M(-44.8%) |
| June 2016 | - | $1.20 M(-53.2%) | $10.63 M(+12.7%) |
| Mar 2016 | - | $2.57 M(-62.6%) | $9.43 M(+14.6%) |
| Dec 2015 | $9.84 M(+93.7%) | - | - |
| Sept 2015 | - | $6.86 M(+400.5%) | $8.23 M(+333.6%) |
| June 2015 | $5.08 M(+271.9%) | - | - |
| Dec 2014 | - | $1.37 M(+159.8%) | $1.90 M(+259.8%) |
| Sept 2014 | - | $527.80 K | $527.80 K |
| June 2014 | $1.37 M | - | - |
FAQ
- What is Adaptimmune Therapeutics annual capital expenditures?
- What is the all time high annual CAPEX for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics annual CAPEX year-on-year change?
- What is Adaptimmune Therapeutics quarterly capital expenditures?
- What is the all time high quarterly CAPEX for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics quarterly CAPEX year-on-year change?
- What is Adaptimmune Therapeutics TTM capital expenditures?
- What is the all time high TTM CAPEX for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics TTM CAPEX year-on-year change?
What is Adaptimmune Therapeutics annual capital expenditures?
The current annual CAPEX of ADAP is $4.88 M
What is the all time high annual CAPEX for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high annual capital expenditures is $29.74 M
What is Adaptimmune Therapeutics annual CAPEX year-on-year change?
Over the past year, ADAP annual capital expenditures has changed by -$24.86 M (-83.59%)
What is Adaptimmune Therapeutics quarterly capital expenditures?
The current quarterly CAPEX of ADAP is $435.00 K
What is the all time high quarterly CAPEX for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high quarterly capital expenditures is $12.49 M
What is Adaptimmune Therapeutics quarterly CAPEX year-on-year change?
Over the past year, ADAP quarterly capital expenditures has changed by +$146.00 K (+50.52%)
What is Adaptimmune Therapeutics TTM capital expenditures?
The current TTM CAPEX of ADAP is $2.37 M
What is the all time high TTM CAPEX for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high TTM capital expenditures is $30.47 M
What is Adaptimmune Therapeutics TTM CAPEX year-on-year change?
Over the past year, ADAP TTM capital expenditures has changed by -$5.11 M (-68.27%)